Maat Pharma Quote - MAAT

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

7.42

Bid

7.40

Ask

7.46

Volume

765

7.42 Day's Range 7.50

6.52 52 Week Range 9.96

Market Cap

86.192M

Previous Close

7.26

Open

7.50

Last Trade

7.42

Last Trade Time

02:12:06

Financial Volume

VWAP

Average Volume (3m)

6,286

Shares Outstanding

11,616,199

Dividend Yield

PE Ratio

0.00

Earnings Per Share (EPS)

Revenue

2.23M

Net Profit

-19.72M

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.maatpharma.com

Headquarters

Lyon, Rhone, Fra

Founded

Maat Pharma SA is listed in the Pharmaceutical Preparations sector of the Euronext with ticker MAAT. The last closing price for Maat Pharma was 7.26 €. Over the last year, Maat Pharma shares have traded in a share price range of 6.52 € to 9.96 €.

Maat Pharma currently has 11,616,199 shares outstanding. The market capitalization of Maat Pharma is 84.33 € million.

MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

The Independent Data Safety and Monitoring Board (DSMB) has recommended that the trial proceeds as planned without modification. Consistent good...

MaaT Pharma annonce des résultats positifs pour l'étude pivotale de Phase 3 ARES évaluant MaaT013 dans la maladie aiguë du greffon contre l'hôte

L'étude a atteint son critère principal d’évaluation avec un taux de réponse globale gastro-intestinale significatif au 28ème jour de 62...

MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

Article 223-16 of the General Regulations of the Financial Markets Authority (AMF - Autorité des Marchés Financiers) Regulatory News: MaaT Pharma...

CORRECTING and REPLACING: MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

MaaT Pharma to host a KOL webinar on December 17th, 2024, to discuss data and the unmet medical need in acute Graft-versus-Host Disease (aGvHD...

MaaT Pharma présente des données actualisées positives pour MaaT013 issues du programme d’accès compassionnel au Congrès Annuel 2024 de l’ASH

MaaT Pharma organise un webinaire avec des experts le 17 décembre 2024 pour détailler les données et échanger sur les besoins médicaux non...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.06	0.815217391304	7.36	7.72	7.26	3229	7.40675917	DE
4	-0.86	-10.38647343	8.28	8.46	7.22	5224	7.79415176	DE
12	-0.92	-11.03117506	8.34	9.96	7.22	6286	8.20132434	DE
26	0.1	1.36612021858	7.32	9.96	6.8	3634	8.0320749	DE
52	0.2	2.77008310249	7.22	9.96	6.52	2680	8.0809471	DE
156	-5.38	-42.03125	12.8	13.55	4.5	1541	8.18248613	DE
260	-6.08	-45.037037037	13.5	14.4	4.5	1677	9.00106954	DE

MAAT - Frequently Asked Questions (FAQ)

What is the current Maat Pharma share price?

The current share price of Maat Pharma is 7.42 €

How many Maat Pharma shares are in issue?

Maat Pharma has 11,616,199 shares in issue

What is the market cap of Maat Pharma?

The market capitalisation of Maat Pharma is EUR 84.33M

What is the 1 year trading range for Maat Pharma share price?

Maat Pharma has traded in the range of 6.52 € to 9.96 € during the past year

What is the reporting currency for Maat Pharma?

Maat Pharma reports financial results in EUR

What is the latest annual turnover for Maat Pharma?

The latest annual turnover of Maat Pharma is EUR 2.23M

What is the latest annual profit for Maat Pharma?

The latest annual profit of Maat Pharma is EUR -19.72M

What is the registered address of Maat Pharma?

The registered address for Maat Pharma is 70 AVENUE TONY GARNIER, LYON, RHONE, 69007

What is the Maat Pharma website address?

The website address for Maat Pharma is www.maatpharma.com

Which industry sector does Maat Pharma operate in?

Maat Pharma operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
ALCYBCybergun	0.0002 € (100.00%)	3.87M
ALRPDRapid Nutrition	0.024 € (37.93%)	5.01M
ALALOAcheterLouerFR	0.009 € (21.62%)	1.19M
EXAExail Technologies	23.75 € (20.56%)	30.34k
HEIAHeineken	75.92 € (11.71%)	717.28k
POXELPoxel	0.2115 € (-21.81%)	492.22k
ALVIOValerio Therapeutics	0.0523 € (-16.98%)	241.88k
ALVERVergnet	0.0005 € (-16.67%)	2.36M
MTRKMotorK Plc	4.01 € (-12.83%)	900
COTYCoty Inc	5.98 € (-10.61%)	1.76k
ATOAtos SE	0.0023 € (0.00%)	192.95M
BCPBanco Comercial Portugues SA	0.5078 € (-0.12%)	6.45M
ALRPDRapid Nutrition	0.024 € (37.93%)	5.01M
ALCYBCybergun	0.0002 € (100.00%)	3.87M
ALVERVergnet	0.0005 € (-16.67%)	2.36M

Nextbigone 7 minutes ago

$1.92 break out @$2.25 MATH video explains why
https://youtu.be/5nGEzVuPzqQ

MATH

Dodger1 10 minutes ago

https: //www.youtube.com/watch?v=sRnxr4XF9yA

:-)

AABB

ducci1 10 minutes ago

Pivot Calcs: SPX Pivot--6062----R1--6082----R2--6096----S1--6048----S2--6028-----SPY Pivot--604----R1--606----S1--603-----ES Pivot--6080-----VIX Pivot 16.06 !!LOL!!

SPY

Dallas-Cowboys 10 minutes ago

Here is a question and answer from Super Micro earnings transcript. Hopefully my copy and paste works.

NVDA

Investor2014 14 minutes ago

Yeah MBAs and lawyers really would be the best at directing science and clinical operations to succesful outcomes every time all the time - at least in some universe somewhere.

AVXL

CelestialOgre14 14 minutes ago

Gonna skyrocket tomorrow

ELTP

Investor2014 17 minutes ago

Yeah lets scrape by as usual with one too small a trial. Then let Anavex look at the data for a couple of years to see if there is angle whereby the endpoints can be fixed to plausibly file with the EMA, but not FDA. That will keep the hope of retail investors up pontificating on message boards and

AVXL

nwsun 26 minutes ago

Seems like it's a race to no bid vs the annual report filing which could add value. It makes no sense to destroy a company that cost money to clean up for no reason whatsoever, when they could have waited two plus years and found another company to buy more timely to their business plan (if they eve

SFLM

racinglad 28 minutes ago

Morning, further to Mike 290, and am also an investor in Pantheon from the UK

PTHRF

ElectricMountain53 31 minutes ago

In short: we're still nowhere near commercial deals. Face the facts.

LWLG

The ELTP King 37 minutes ago

I'm having trouble sleeping.

Here's why: "Financials for the Third Quarter of Fiscal Year 2025 Ended December 31, 2024 will be released on Thursday, February 13, 2025"

ELTP

tradero 37 minutes ago

More quotes:

"...And I think in the last decade is looking how you would speed up optical modulation.

And there's many technologies to do that. The the one we worked on was electro optic polymers. I mean, that has a huge potential. I'd say mother nature works with the p

LWLG

RickNagra 46 minutes ago

Get lost Ron.

FNMA

Dodger1 47 minutes ago

re·dun·dan·cy best I could spell.

Over a hundred years you see..time to save or keep printing
currency?

Save or Invest or Why???or What??

$AABB $AABBG

AABB

Nrdc92 47 minutes ago

We'll probably be in the $1.20s come June, when we will be ceremoniously dropped by the Russell 3000, and the stock will plummet to under $1 overnight. This will be followed by a reverse split and, ultimately, bankruptcy by the end of 2025-mid '26. Multiple derivative suits will be filed, and the BO

LWLG

9Coastal 49 minutes ago

Article excerpt: "Cryoablation was the only thermal ablative technique that met the minimum requirements and will therefore be selected for the Phase 3 trial.". Go Israel! Steady she goes..

ICCM

tradero 51 minutes ago

Quote from the Podcast:

"...But I think the exciting part was what do you need to do to take something that was, you know, okay, we can write a research paper on it and we can make it work in a lab. But how do you get everybody to use it?

And I think this is the same dr

LWLG

copytele 51 minutes ago

WOW!>>>>> WHAT HAPPENED YESTERDAY?

RGTI

KOmani 54 minutes ago

Let us know what you can find about any of the company's named below:

Wanding Qianghua Youshang (Sichuan) Technology Co., Ltd.

Sichuan Huatai Aiji Health Management Co., Ltd.

The PR says they made 150 Million RMB in revenue and yet you can not find anythi

TRII

zakattack 55 minutes ago

I just want to know if gncp still has a future is their a plan or is it just nothing

GNCP

BrandonSmith1 55 minutes ago

FYI I haven't logged in for a bit. But here's how pathetic Auri Token is doing. It's a big sh*t coin down the toilet.

https://www.livecoinwatch.com/price/Auricoin-AURI

AURI

Dodger1 60 minutes ago

https ://www.youtube.com/watch?v=nUUyFrHERpU

then

https ://www.youtube.com/watch?v=--AvCsh48bk

Love $AABB

AABB

dinogreeves 1 hour ago

Targets 40 billion revenue by 2026. 200 dollars here we come after the audit report.

SMCI

236T568 1 hour ago

It was deleted

236T568 1 hour ago

Geesh. You see this? Dudes are going in the wrong direction.

https://x.com/acnewsitics/status/1889123582862581824?s=19

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Maat Pharma SA (MAAT)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

About Maat Pharma SA

Ask ADVFN Intelligence (AI)

MAAT Latest News

MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

MaaT Pharma annonce des résultats positifs pour l'étude pivotale de Phase 3 ARES évaluant MaaT013 dans la maladie aiguë du greffon contre l'hôte

MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

CORRECTING and REPLACING: MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

MaaT Pharma présente des données actualisées positives pour MaaT013 issues du programme d’accès compassionnel au Congrès Annuel 2024 de l’ASH

MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

MaaT Pharma annonce des résultats positifs pour l'étude pivotale de Phase 3 ARES évaluant MaaT013 dans la maladie aiguë du greffon contre l'hôte

MaaT Pharma : Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social

CORRECTING and REPLACING: MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

MaaT Pharma Announces First U.S. Patient Treated at City of Hope Under Single Patient Expanded Access for MaaT013 in Acute Graft-versus-Host Disease

MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS)

MaaT Pharma to Present Updates from Early Access Program at the 2024 ASH Annual Meeting Demonstrating Prolonged Long-Term Survival in Patients Receiving MaaT013 in aGvHD

MAAT - Frequently Asked Questions (FAQ)

Movers

Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Maat Pharma SA (MAAT) Share Price

Maat Pharma SA (MAAT)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

About Maat Pharma SA

Ask ADVFN Intelligence (AI)

MAAT Latest News

MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

MaaT Pharma annonce des résultats positifs pour l'étude pivotale de Phase 3 ARES évaluant MaaT013 dans la maladie aiguë du greffon contre l'hôte

MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

CORRECTING and REPLACING: MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

MaaT Pharma présente des données actualisées positives pour MaaT013 issues du programme d’accès compassionnel au Congrès Annuel 2024 de l’ASH

MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

MaaT Pharma annonce des résultats positifs pour l'étude pivotale de Phase 3 ARES évaluant MaaT013 dans la maladie aiguë du greffon contre l'hôte

MaaT Pharma : Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social

CORRECTING and REPLACING: MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

MaaT Pharma Announces First U.S. Patient Treated at City of Hope Under Single Patient Expanded Access for MaaT013 in Acute Graft-versus-Host Disease

MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS)

MaaT Pharma to Present Updates from Early Access Program at the 2024 ASH Annual Meeting Demonstrating Prolonged Long-Term Survival in Patients Receiving MaaT013 in aGvHD

MAAT - Frequently Asked Questions (FAQ)

Movers

Discussion

Your Recent History

Company

Business

Popular

Get The App

Go Ad-Free